SummaryBackgroundStudies have suggested that the prevalence of dementia is lower in developing than in developed regions. We investigated the prevalence and severity of dementia in sites in low-income and middle-income countries according to two definitions of dementia diagnosis.MethodsWe undertook one-phase cross-sectional surveys of all residents aged 65 years and older (n=14 960) in 11 sites in seven low-income and middle-income countries (China, India, Cuba, Dominican Republic, Venezuela, Mexico, and Peru). Dementia diagnosis was made according to the culturally and educationally sensitive 10/66 dementia diagnostic algorithm, which had been prevalidated in 25 Latin American, Asian, and African centres; and by computerised application of the dementia criterion from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). We also compared prevalence of DSM-IV dementia in each of the study sites with that from estimates in European studies.FindingsThe prevalence of DSM-IV dementia varied widely, from 0·3% (95% CI 0·1–0·5) in rural India to 6·3% (5·0–7·7) in Cuba. After standardisation for age and sex, DSM-IV prevalence in urban Latin American sites was four-fifths of that in Europe (standardised morbidity ratio 80 [95% CI 70–91]), but in China the prevalence was only half (56 [32–91] in rural China), and in India and rural Latin America a quarter or less of the European prevalence (18 [5–34] in rural India). 10/66 dementia prevalence was higher than that of DSM-IV dementia, and more consistent across sites, varying between 5·6% (95% CI 4·2–7·0) in rural China and 11·7% (10·3–13·1) in the Dominican Republic. The validity of the 847 of 1345 cases of 10/66 dementia not confirmed by DSM-IV was supported by high levels of associated disability (mean WHO Disability Assessment Schedule II score 33·7 [SD 28·6]).InterpretationAs compared with the 10/66 dementia algorithm, the DSM-IV dementia criterion might underestimate dementia prevalence, especially in regions with low awareness of this emerging public-health problem.FundingWellcome Trust (UK); WHO; the US Alzheimer's Association; and Fondo Nacional De Ciencia Y Tecnologia, Consejo De Desarrollo Cientifico Y Humanistico, and Universidad Central De Venezuela (Venezuela).
The persistent and near-infrared photostimulated optical properties of CaS nanoparticles and CaS:Eu 2+ and CaS:Eu 2+ ,Dy 3+ nanophosphors are presented. Proposed mechanisms are elucidated for both phenomena by carrying out wavelength-resolved, thermally stimulated luminescence (TSL) and photostimulated luminescence (PSL) measurements. After UV (254 nm) irradiation, blue persistent and near-infrared photostimulated luminescence is obtained due to the presence of intrinsic defects in CaS nanoparticles. By introducing Eu 2+ as a dopant, the formation of shallow traps below the conduction band is observed and red persistent and near-infrared PSL is obtained. Dy 3+ is added as a codopant to create shallow and near-infrared photostimulated deeper traps, lengthening the strong red persistent luminescence to 5 h and PSL time to 18 min.at 254 nm at a power of 6 W for 10 min and a maximum PSL time of 18 ± 2 min using 980 nm excitation at powers as low as 29 mW.
The performance of a persistent phosphor is often determined by comparing luminance decay curves, expressed in cd/m2. However, these photometric units do not enable a straightforward, objective comparison between different phosphors in terms of the total number of emitted photons, as these units are dependent on the emission spectrum of the phosphor. This may lead to incorrect conclusions regarding the storage capacity of the phosphor. An alternative and convenient technique of characterizing the performance of a phosphor was developed on the basis of the absolute storage capacity of phosphors. In this technique, the phosphor is incorporated in a transparent polymer and the measured afterglow is converted into an absolute number of emitted photons, effectively quantifying the amount of energy that can be stored in the material. This method was applied to the benchmark phosphor SrAl2O4:Eu,Dy and to the nano-sized phosphor CaS:Eu. The results indicated that only a fraction of the Eu ions (around 1.6% in the case of SrAl2O4:Eu,Dy) participated in the energy storage process, which is in line with earlier reports based on X-ray absorption spectroscopy. These findings imply that there is still a significant margin for improving the storage capacity of persistent phosphors.
We report on the synthesis, the characterization and the optical properties of CaS:Eu 2+ /Dy 3+ nanophosphors. We demonstrate the generation of strong red light emission following NIR excitation of the CaS:Eu 2+ /Dy 3+ nanophosphors.
Lanthanide-doped upconverting nanoparticles (Ln-UCNPs) possess optical and physicochemical properties that are promising for the design of new theranostic platforms. This applies in particular to the treatment of cancer. Towards this goal, oleate-capped-NaLuF4:Tm3+(0.5%)/Yb3+(20%)/Gd3+(30%) with an average size of 35 nm ± 2 nm were synthesized by co-precipitation. Due to their hydrophobic surface, these Ln-UCNPs produced agglomerates under cell culture conditions. To assess the cellular response to Ln-UCNPs at the molecular level, we evaluated several key aspects of tumor cell physiology. Using cancer lines of different origins, we demonstrated Ln-UCNP dependent changes of cancer cell biomarkers. Multiple cellular components that regulate tumorigenesis and cancer cell homeostasis were affected. In particular, Ln-UCNPs reduced the abundance of hsp70s, elevated DNA damage, and diminished nucleolin and B23/nucleophosmin, proteins required for the assembly of ribosomes. Treatment with Ln-UCNPs also decreased the concentration of paxillin, a focal adhesion protein that is involved in directed cell migration. Furthermore, epidermal growth factor (EGFR) levels were decreased by Ln-UCNPs for most cancer cell lines examined. Taken together, we identified several potential cancer cell targets that were affected by Ln-UCNPs. Our work thereby provides the foundation to optimize Ln-UCNPs for the targeted killing of tumor cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.